BioRestorative Concludes Phase II BRTX-100 Trial Enrolment for cLDD
BioRestorative Therapies announced completion of patient enrollment for its Phase II BRTX‑100 trial in chronic lumbar disc disease, enrolling 99 subjects at 15 U.S. sites. The double‑blind, sham‑controlled study randomizes participants 2:1 to receive an autologous hypoxically cultured mesenchymal stem cell injection or placebo via a minimally invasive intradiscal procedure. Primary safety and efficacy endpoints focus on adverse event rates and achieving at least a 30 % improvement in Oswestry Disability Index and pain scores by week 52. Preliminary blinded data and a recent FDA Type B meeting suggest a clear path toward Phase III and a potential biologics license application.
Eight Biotech Companies Spearheading the Antibody Drug Conjugate New Wave
A new wave of eight biotech firms is redefining antibody‑drug conjugates (ADCs) by pursuing unconventional targets, advanced linker chemistries, and novel cytotoxic payloads. Companies such as Adcendo, Adcentrx, and Tubulis are advancing phase 1/2 programs that address sarcoma, Nectin‑4, NaPi2b, and...
Developing a Risk-Scoring Tool for Artificial Intelligence-Enabled Biological Design
Researchers at RAND released a risk‑scoring framework to evaluate AI‑enabled biological design threats. The tool separates biological modification impact across five functions—host range, replication, immune evasion, environmental stability, and transmission—and an actor capability dimension that gauges technical skill and AI...
A One Two Gene Therapy Punch to Non-Muscle Invasive Bladder Cancer
The episode explores EnGene's experimental gene therapy, detalimogene, for treating non‑muscle invasive bladder cancer, a condition affecting half a million new patients annually. Ron Cooper, EnGene's CEO, explains how the therapy uses a non‑viral vector to deliver a dual payload...
Gilead Dips as ‘Strong’ Earnings Outweighed by High Expectations for New HIV Drug
Gilead Sciences reported a strong fourth‑quarter, with product sales reaching $7.9 billion, a 5% year‑over‑year increase, and its flagship HIV treatments Biktarvy and Descovy surpassing analyst forecasts. The company projected full‑year sales of $29.6‑$30 billion and EPS of $8.45‑$8.85, staying within consensus...
A Thousand Physicians Call on FDA to Reverse CRL for Myopia Drug
More than a thousand physicians have signed a citizen petition urging the FDA to overturn its complete response letter (CRL) rejecting SYD‑101, Sydnexis Inc.'s pediatric myopia treatment. The company met the agency‑specified primary endpoint, but the FDA concluded the data...
FDA’s Accelerated Approval Messaging Collides with CRL Reality
The FDA issued a complete response letter (CRL) rejecting Regenxbio’s accelerated‑approval application for clemidsogene lanparvovec, a gene therapy targeting Hunter syndrome (MPS II). The decision underscores a growing disconnect between the agency’s public messaging on accelerated pathways and its actual regulatory...
Moderna Says FDA Refuses to Review Its Application for Experimental Flu Shot
Moderna announced that the FDA will not begin a review of its experimental mRNA‑1010 flu vaccine, citing concerns over the trial's comparator design rather than safety or efficacy. The decision triggered a roughly 7% drop in Moderna’s after‑hours share price....
Software Tool Can Detect Hidden Errors in Complex Tissue Analyses
A new software tool called ovrlpy, developed by the Berlin Institute of Health at Charité, detects hidden errors in spatial transcriptomics by identifying vertically overlapping cells and tissue folds. Published in Nature Biotechnology, the tool is the first to analyze...
Brain Stimulation Encourages More Altruistic Behavior, Study Finds
Researchers applied transcranial alternating current stimulation to synchronize gamma oscillations between frontal and parietal cortices, leading participants to share more money in the Dictator Game. The experiment involved 44 adults who each made 540 allocation decisions, providing a robust behavioral...
Isomorphic Claims Major Advance with New AI Drug Design Engine
Isomorphic Labs, the DeepMind spin‑off behind AlphaFold 3, announced a new AI‑driven drug design engine that builds on its protein‑structure predictions. The platform claims to generate novel small‑molecule candidates up to ten times faster while achieving sub‑nanomolar binding‑affinity accuracy. Early validation...
Researchers Discover Molecular Switch Regulating T Cell Exhaustion in Cancer
An international team led by Prof. Guideng Li and Dr. Philip D. Greenberg identified a molecular switch that drives CD8⁺ T‑cell exhaustion in cancer. Chronic TCR signaling phosphorylates FOXO1, suppressing transcription of the E3 ligase KLHL6, which normally degrades the...
Google's AI Drug Discovery Spinoff Isomorphic Labs Claims Major Leap Beyond AlphaFold 3
Isomorphic Labs, the AI medicine arm of Google DeepMind, unveiled the Isomorphic Labs Drug Design Engine (IsoDDE), claiming it outperforms AlphaFold 3 in protein‑ligand structure prediction. The company reports that IsoDDE doubles AlphaFold 3’s accuracy on novel protein‑ligand pairs and delivers rapid...
AbbVie, AstraZeneca Lose Appeal in Louisiana 340B Contract Pharmacy Fight
A U.S. appeals court upheld Louisiana's law that restricts how 340B‑discounted drugs can be dispensed through contract pharmacies. The ruling rejected the challenge mounted by AbbVie and AstraZeneca, marking another defeat for drugmakers contesting state oversight of the federal 340B...
NIH Stops Low-Dose Xarelto Arm of Large Stroke Study Due to Safety Concerns
The National Institutes of Health has stopped the low‑dose Xarelto arm of a large, multi‑center stroke trial after an interim safety analysis revealed excess bleeding. The study, which enrolled roughly 5,000 patients with recent ischemic stroke, was testing rivaroxaban 2.5 mg...
University of South Alabama Research Recognized Among Top 10 Scientific Breakthroughs of 2025
The University of South Alabama’s research portfolio was named one of the top ten scientific breakthroughs of 2025. The accolade highlights a suite of studies ranging from a novel photofission method for producing medical isotope 99Mo to a molecular switch...
A Reinvigorated Alcor and Growth in Cryonics
The post highlights Alcor’s recent surge in funding and operational upgrades, marking a turning point for the cryonics sector. New initiatives include the first in‑house whole‑body CT scan for real‑time vitrification assessment, improved organ‑preservation protocols, and pioneering brain‑slice culture experiments....
Researchers Rebuild Microscopic Circadian Clock that Can Control Genes
Scientists at UC San Diego and collaborators have reconstituted the minimal cyanobacterial circadian clock using just six proteins, demonstrating precise control of gene transcription through RpaA phosphorylation. The team built a synthetic clock that rhythmically drives a reporter gene in...
Merck Foundation Grant Advances Cardiovascular Care for Formerly Incarcerated Black Men
The Merck Foundation has awarded a five‑year, $1.75 million grant to a partnership between University of Chicago Medicine and Lawndale Christian Health Center to improve cardiovascular outcomes for formerly incarcerated Black men in Chicago’s North Lawndale. The program combines clinical management...
UCalgary Research Explores Common Vitamin as Potential Treatment for Aggressive Glioblastoma Brain Cancer
University of Calgary researchers launched a Phase I/II trial testing high‑dose vitamin B3 (niacin) alongside standard surgery, radiation, and chemotherapy for newly diagnosed glioblastoma. The study enrolled 24 patients and reported an 82% progression‑free rate at six months, a 28% improvement...
NIST Awards Over $3M to Small Businesses Advancing AI, Biotech, Semiconductors, Quantum and More
The National Institute of Standards and Technology (NIST) has awarded $3.19 million in Phase II SBIR grants to eight small businesses across seven states. The funding supports research in artificial intelligence, biotechnology, semiconductor, quantum and other advanced technologies, with each award ranging...
Learn With Me: $2M Insight, Fractional Cost
In 2020, I hired McKinsey to teach me about the global energy transition. I learned a lot, but it cost me more than $2M. After that experience, I decided to build my own internal research project at Social Capital called Learn...
A New Inhalable Treatment for Tuberculosis: Once-Weekly Nanoparticles Match Daily Oral Rifampin in Mice
Researchers at the University at Buffalo have created an inhalable nanoparticle that encapsulates rifampin and can be administered once weekly, matching the efficacy of daily oral dosing in mouse models of tuberculosis. The biodegradable particles target lung macrophages, sustain drug...
Versatile Enzyme that Quickly, Accurately Synthesizes RNA Can Also Perform Reverse Transcription
Scientists at UC Irvine have engineered a novel polymerase, C28, that synthesizes RNA at speeds comparable to natural enzymes while maintaining high fidelity. Using directed evolution, the team introduced dozens of mutations that also grant the enzyme reverse‑transcription capability and...
Hypersensitive Detection of Millimeter Vascular Emboli In Vivo
Scientists reported a hypersensitive method to detect single millimeter‑sized vascular emboli in vivo. The technique combines near‑infrared fluorescence imaging with specially engineered adhesive tracers that attach to clot surfaces under physiological blood flow. It enables real‑time, non‑invasive visualization of emboli...
After T-DXd: Target, Payload, or Something Else?
The article examines the split debate over trastuzumab deruxtecan (T‑DXd) resistance, questioning whether the drug’s payload has failed or the tumor has lost HER2 engagement. Both mechanisms are supported by data, and the true challenge lies in identifying which drives...
Optimizing Post-Denosumab Treatment Approaches in Non-Metastatic Breast Cancer Patients Undergoing AI Therapy
Aromatase inhibitors (AIs) are cornerstone adjuvant therapies for hormone‑receptor‑positive breast cancer but accelerate bone loss, prompting routine use of denosumab to prevent fractures. While denosumab effectively suppresses bone turnover during AI treatment, abrupt discontinuation triggers a rebound surge in osteoclast...
AI-Generated Arguments Prove Persuasive Despite Disclosure
A new study of 1,601 Americans finds that labeling a message as AI‑generated does not reduce its persuasive power compared with human‑authored or unlabeled content. Across four policy topics, AI‑crafted arguments shifted opinions by roughly 9.7 percentage points, and 92 %...
Vimseltinib
Deciphera Pharmaceuticals received FDA approval for vimseltinib, an oral, selective CSF1R kinase inhibitor, to treat tenosynovial giant cell tumor (TGCT). The drug emerged from structure‑based drug design (SBDD) and extensive SAR optimization, as reported in Bioorganic & Medicinal Chemistry Letters...
Unveiling Muscle Viscoelasticity’s Impact in Heart Failure
The VISMARC‑HF study will examine how skeletal‑muscle viscoelasticity correlates with prognosis in older heart‑failure patients. Researchers will recruit participants across disease stages and use advanced imaging and biomechanical testing to quantify muscle elasticity and viscosity. By linking these biomechanical metrics...
Revolutionary AI Model Enhances Precision in Detecting Food Contamination
A new artificial‑intelligence model has been unveiled that dramatically improves the detection of microbial and chemical contaminants in food products. Leveraging multimodal imaging, hyperspectral data, and deep‑learning algorithms, the system reports a 98% detection accuracy across a range of common...
Insilico Medicine and CMS Forge Multiple Collaborations to Accelerate AI-Driven R&D in CNS and Autoimmune Disorders
Insilico Medicine and China Medical System Holdings (CMS) announced a multi‑project partnership to apply Insilico’s Pharma.AI platform to drug discovery for central nervous system and autoimmune diseases. The AI system promises to deliver preclinical candidates within 12‑18 months, a dramatic...
Novel Nanosheets Boost Clot Clearing While Limiting Systemic Bleeding
Researchers in China have unveiled a silicon‑based nanothrombolytic platform that couples urokinase with hydrogenated silicene (SiH) nanosheets and fibrinogen to clear arterial clots. The SiH sheets temporarily inhibit urokinase during circulation, then self‑degrade at the thrombus, reactivating the drug and...
Video: Can Robots Help Save Farming?
Robotics, AI, and automation are reshaping UK agriculture as the Lincoln Institute for Agri‑Food Technology (LIAT) showcases its latest innovations. The institute’s autonomous ARWAC field machine, the data‑rich HiRes‑Soils project, and Saga Robotics’ Thorvald harvest‑assist robot illustrate how technology can...
FDA Kicks Off Review of Takeda's Narcolepsy Hopeful
The U.S. Food and Drug Administration has placed Takeda's orexin‑2 receptor agonist oveporexton (TAK‑861) into a priority review, with a decision expected in the third quarter. If approved, it would become the first drug to target the underlying orexin deficiency...
Evommune Soars as Dermatitis Treatment Rivals Dupixent in Mid-Stage Trial
Evommune’s shares surged 75% after its Phase 2a trial showed the therapeutic protein EVO301 reduced atopic dermatitis severity by 33% versus placebo. The study enrolled 70 patients, with a 55% reduction in the treatment arm compared to 22% in the placebo...
Scientists Identify Genetic Connection to Barrett’s Esophagus, Paving the Way for Advances in Esophageal Cancer Treatment
Researchers at Case Western Reserve University identified mutations in the VSIG10L gene as a key hereditary driver of Barrett’s esophagus, a precursor to esophageal adenocarcinoma. The study analyzed genetic data from 684 individuals across 302 families and demonstrated that loss‑of‑function...
Silent Witnesses: Pets Offer a Fur-Ensic Tale
Researchers at Flinders University and Victoria Police have demonstrated that dogs and cats can act as intermediaries for human DNA transfer at crime scenes. Controlled experiments showed even brief contact leaves detectable DNA on pets, which can then be deposited...
Aramis Biotechnologies and the Biologics Manufacturing Centre (BMC) Inc. – Announce the Successful Delivery of a Seasonal Influenza Vaccine in...
Aramis Biotechnologies and the Biologics Manufacturing Centre (BMC) announced they have completed formulation, aseptic fill‑finish, and clinical packaging for Aramis’s seasonal influenza vaccine. The milestone delivers clinical‑grade material for Phase 1/2 trials, meeting regulatory quality and safety requirements. The achievement underscores...
Biomolecular Condensates in Pro-Β-Carboxysome Assembly
A new Nature Plants study reveals that biomolecular condensates, formed through liquid‑liquid phase separation, drive the multistage assembly of pro‑β‑carboxysomes in cyanobacteria. Scaffold proteins and post‑translational modifications orchestrate condensate nucleation, growth, and a liquid‑to‑gel transition that stabilizes the microcompartment. Environmental...
RegASK Launches AI-Assisted Label Review Delivering Compliance Reports in Seconds Across Global Markets
RegASK unveiled an AI‑Assisted Label Compliance Review that checks packaging labels in seconds across major markets such as the US, EU, UK and China. The tool pairs instant AI analysis with an interactive viewer that highlights violations and links directly...
Astellas’ “Strategic Brands” And “Primary Focuses” After XTANDI
Astellas is reshaping its portfolio as XTANDI nears patent expiry, shifting from a single‑product reliance to a set of “strategic brands.” The company is promoting approved assets such as PADCEV, VYLOY, VEOZAH and IZERVAY to smooth revenue across oncology, menopause...
Women in STEM: Unique Impacts in Rare Disease Development
Klaudia Lechowska, a business‑development specialist at Mabion Biologics, highlighted how STEM education equips women with both technical and commercial skills essential for biotech careers. She noted that women comprise about 60% of the pharma workforce but hold only a quarter...
Perinatal Microplastic Exposure Alters Neonatal Immunity, Metabolism
A new scoping review in the Journal of Perinatology reveals that micro‑ and nano‑plastics can cross the placental barrier and be transmitted through breast milk, exposing fetuses and neonates to particulate pollutants. The exposure triggers chronic inflammation, oxidative stress, and...
Rezpeg Shows Higher 1‑Year EASI75 Rates Than Dupixent
Lot's caveats to this as it's a rough calculation, but given higher maintenance of EASI75 responses on $NKTR Q12W regimen and a very similar absolute rate of EASI75 on induction when compare to Dupixent... ...A higher proportion of patients achieve EASI75...
Exploring Cutting-Edge Automated Lab Gear at SLAS Boston
SLAS is going on in Boston right now. We’re checking out a lot of cool automated lab equipment this week. https://t.co/CSFO1oGnt7
AstraZeneca CEO Hails NHS Drug Price Deal but Keeps Pause on £200m UK Investment
AstraZeneca CEO Pascal Soriot praised the UK‑US NHS drug‑pricing agreement as a "very positive step," but said it will not unlock the paused £200 million Cambridge research hub investment. The deal is projected to cost the NHS about £1 billion over its...
New Study Uncovers How Chills Develop and Bolster the Body’s Defense Against Infection
Researchers at Nagoya University identified the brain circuit that generates chills during infection. They showed that prostaglandin E₂ acting on EP3 receptors in the lateral parabrachial nucleus (LPB) triggers warmth‑seeking behavior without invoking shivering. EP3‑positive LPB neurons project to the central...
CSL’s Paul McKenzie Out, as Gordon Naylor Named Interim CEO
CSL Limited announced that CEO Paul McKenzie will step down immediately after more than five years with the Australian biotech group. The board appointed Gordon Naylor, a veteran pharma executive, as interim chief executive. The decision reflects the board’s view...
DDW Highlights: 10 February 2026
In this 15‑minute episode, DDW host Bruno Quinney recaps five major stories from the past week, highlighting breakthrough cancer therapies that promise greater efficacy and safety, and new research aimed at enhancing brain function in Alzheimer’s patients. He also touches...